Citations

Clear

19 citation(s) found for "Lee, Alexander".

Open and arthroscopic management of femoroacetabular impingement: a review of current concepts
Hassan, Mahad M. , Farooqi, Ali S. , Feroe, Aliya G. , Lee, Alexander , Novais, Eduardo N. , Wuerz, Thomas H., Kim, Young‐Jo , Cusano, Antonio , Parisien, Robert L.

Mayo Clinic

Journal of Hip Preservation Surgery | October 13, 2022 | Volume: 9 | Issue: 4 | Pages: 265-275

10.1093/jhps/hnac043 | PMID 36908557 Get It

ABSTRACTFemoroacetabular impingement (FAI) is a common femoral and/or acetabular abnormality that can cause progressive damage to the hip and osteoarthritis. FAI can be the result of femoral head/neck overgrowth, acetabular overgrowth or both femoral and acetabular abnormalities, resulting in a loss of native hip biomechanics and pain upon hip flexion and rotation. Radiographic evidence can include loss of sphericity of the femoral neck (cam impingement) and/or acetabular retroversion with focal or global overcoverage (pincer impingement). Operative intervention is indicated in symptomatic patients after failed conservative management with radiographic evidence of impingement and minimal arthritic changes of the hip, with the goal of restoring normal hip biomechanics and reducing pain. This is done by correcting the femoral head–neck relationship to the acetabulum through femoral and/or acetabular osteoplasty and treatment of concomitant hip pathology. In pincer impingement cases with small lunate surfaces, reverse periacetabular osteotomy is indicated as acetabular osteoplasty can decrease an already small articular surface. While surgical dislocation is regarded as the traditional gold standard, hip arthroscopy has become widely utilized in recent years. Studies comparing both open surgery and arthroscopy have shown comparable long-term pain reduction and improvements in clinical measures of hip function, as well as similar conversion rates to total hip arthroplasty. However, arthroscopy has trended toward earlier improvement, quicker recovery and faster return to sports. The purpose of this study was to review the recent literature on open and arthroscopic management of FAI.
Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial
Gounder, Mrinal M. , Razak, Albiruni Abdul , Somaiah, Neeta , Chawla, Sant P. , Martín‐Broto, Javier , Schuetze, Scott M. , Vincenzi, Bruno , Wagner, Andrew J. , Chmielowski, Bartosz , Jones, Robin L. , Riedel, Richard F. , Stacchiotti, Silvia , Ganjoo, Kristen N. , Cesne, Axel Le , Italiano, Antoîne , Ryan, Christopher W. , Mulcahy, Mary F. , Forscher, Charles, Okuno, Scott H. , Hartner, Lee , Philip, Tony , Alcindor, Thierry , Reichardt, Peter , Chevreau, Christine , Morales, Claudia Maria Valverde, Chen, James L. , Deshpande, Hari A. , Nicholas, Garth , Gröschel, Stefan , Hatcher, Helen, Duffaud, Florence , Beveridge, Roberto Díaz, Meyer, Christian F. , Götze, Katharina S. , Mazzeo, F , Yakobson, Alexander, Zick, Aviad , Lee, Alexander T.J. , Estival, Anna , Napolitano, Andrea , Dickson, Mark A. , Michel, Dayana , Meng, Changting , Ben‐Shahar, Osnat , Chang, Hua, Landesman, Yosef , Shah, Jatin J., Shacham, Sharon, Kauffman, Michael , Attia, Steven , Schuetze, Scott M , Vincenzi, Bruno , Wagner, Andrew J , Chmielowski, Bartosz , Jones, Robin L , Riedel, Richard F , Loggers, Elizabeth T , Le Cesne, Axel , Italiano, Antoine , Garcia Del Muro, Xavier , Mulcahy, Mary F , Penel, Nicolas , Okuno, Scott , Elias, Anthony D , Hartner, Lee , Philip, Tony , Alcindor, Thierry , Lapeire, Lore , Blay, Jean-Yves , Chen, James L , Davis, Elizabeth J , Hatcher, Helen , Meyer, Christian , von Mehren, Margaret , Van Tine, Brian A , Götze, Katharina , Mazzeo, Filomena , Zick, Aviad , Lee, Alexander , Gonzalez, Anna Estival , Napolitano, Andrea , Michel, Dayana , Meng, Changting , Ben-Shahar, Osnat , Van Domelen, Dane R , Grignani, Giovanni , Burgess, Melissa , Piperno‐Neumann, Sophie , Elias, Anthony , Kasper, Bernd , Blay, Jean‐Yves , Schwartz, Gary K. , Davis, Elizabeth J. , Casado, Antonio , Badalamenti, Giuseppe , Eriksson, Mikael , Mehren, Margaret von , Tine, Brian A. Van , Li, Lingling , Liu, Jianjun , Walker, Christopher James

Mayo Clinic

Journal of Clinical Oncology | April 8, 2022 | Volume: 40 | Issue: 22 | Pages: 2479-2490

10.1200/jco.21.01829 | PMID 35394800 Get It

PURPOSE Antitumor activity in preclinical models and a phase I study of patients with dedifferentiated liposarcoma (DD-LPS) was observed with selinexor. We evaluated the clinical benefit of selinexor in patients with previously treated DD-LPS whose sarcoma progressed on approved agents. METHODS SEAL was a phase II-III, multicenter, randomized, double-blind, placebo-controlled study. Patients age 12 years or older with advanced DD-LPS who had received two-five lines of therapy were randomly assigned (2:1) to selinexor (60 mg) or placebo twice weekly in 6-week cycles (crossover permitted). The primary end point was progression-free survival (PFS). Patients who received at least one dose of study treatment were included for safety analysis (ClinicalTrials.gov identifier: NCT02606461 ). RESULTS Two hundred eighty-five patients were enrolled (selinexor, n = 188; placebo, n = 97). PFS was significantly longer with selinexor versus placebo: hazard ratio (HR) 0.70 (95% CI, 0.52 to 0.95; one-sided P = .011; medians 2.8 v 2.1 months), as was time to next treatment: HR 0.50 (95% CI, 0.37 to 0.66; one-sided P < .0001; medians 5.8 v 3.2 months). With crossover, no difference was observed in overall survival. The most common treatment-emergent adverse events of any grade versus grade 3 or 4 with selinexor were nausea (151 [80.7%] v 11 [5.9]), decreased appetite (113 [60.4%] v 14 [7.5%]), and fatigue (96 [51.3%] v 12 [6.4%]). Four (2.1%) and three (3.1%) patients died in the selinexor and placebo arms, respectively. Exploratory RNA sequencing analysis identified that the absence of CALB1 expression was associated with longer PFS with selinexor compared with placebo (median 6.9 v 2.2 months; HR, 0.19; P = .001). CONCLUSION Patients with advanced, refractory DD-LPS showed improved PFS and time to next treatment with selinexor compared with placebo. Supportive care and dose reductions mitigated side effects of selinexor. Prospective validation of CALB1 expression as a predictive biomarker for selinexor in DD-LPS is warranted.
Impact of mitral intervention on outcomes of patients with mitral valve dysfunction and annulus calcification
Kato, Nahoko , Pellikka, Patricia A. , Lee, Alexander T., Jain, Vaibhav , Eleid, Mackram F. , Reeder, Guy S., Bagameri, Gabor, Rihal, Charanjit S. , Eleid, Mackram F , Alkhouli, Mohamad A, Guerrero, Mayra E , Pellikka, Patricia A , Scott, Christopher G. , Alkhouli, Mohamad , Michelena, Héctor I. , Pislaru, Sorin V. , Crestanello, Juan A. , Rihal, Charanjit S. , Guerrero, Mayra

Mayo Clinic

Catheterization and Cardiovascular Interventions | January 23, 2022 | Volume: 99 | Issue: 6 | Pages: 1807-1816

10.1002/ccd.30093 | PMID 35066988 Get It

AbstractObjectivesTo compare all‐cause mortality in patients with mitral annulus calcification (MAC) and severe mitral valve dysfunction (MVD) who received standard mitral intervention versus no intervention.BackgroundPatients with MAC often have high surgical risk due to advanced age, comorbidities, and technical challenges related to calcium. The impact of a mitral intervention on outcomes of patients with MAC and severe MVD is not well known.MethodsRetrospective review of patients with MAC by transthoracic echocardiography (TTE) in 2015 at a single institution. Patients with severe mitral stenosis (MS) or regurgitation (MR) were analyzed and stratified into two groups: surgical or transcatheter intervention performed <1 year after the index TTE, and no or later intervention. The primary endpoint was all‐cause mortality.ResultsOf 5502 patients with MAC, 357 had severe MVD (MS = 27%, MR = 73%). Of those, 108 underwent mitral intervention (surgery = 87; transcatheter = 21). They were younger (73 ± 11 vs. 76 ± 11 years, p < 0.01) and less frequently had cardiovascular diseases compared with no‐intervention. Frequency in women was similar (45% vs. 50%, p = 0.44). During median follow‐up of 3.2 years, the intervention group had higher estimated survival than those without intervention (80% vs. 72% at 1 year and 55% vs. 35% at 4 year, p < 0.01). Adjusted for age, eGFR, LVEF < 50%, and pulmonary hypertension, mitral intervention was an independent predictor of lower mortality (hazard ratio = 0.66, 95% confidence interval 0.43–0.99, p = 0.046).ConclusionPatients with MAC and severe MVD who underwent mitral intervention <1 year from index TTE had lower mortality than those without intervention. Mitral intervention was independently associated with lower mortality.
Effect of Shared Decision‐Making for Stroke Prevention on Treatment Adherence and Safety Outcomes in Patients With Atrial Fibrillation: A Randomized Clinical Trial
Noseworthy, Peter A. , Branda, Megan E. , Kunneman, Marleen , Hargraves, Ian , Sivly, Angela , Brito, Juan P. , Burnett, Bruce , Zeballos‐Palacios, Claudia , Suzuki, Takeki , Lee, Alexander T., Gorr, Haeshik, McCarthy, Sarah , Shah, Nilay D. , Fleming, Kirsten, Haffke, Alexander, Muegge, Jule , Poplau, Sara , Simpson, Benjamin , Vang, Miamoua, Wambua, Mike , Anderson, Joel, Behnken, Emma , Cabalka, Renee, Ferrara, Michael J. , Giblon, Rachel , Inselman, Jonathan , Olive, Marc, Organick, Paige, Spencer‐Bonilla, Gabriela , Stier, Amy, Thota, Anjali, Ting, Henry H. , Vanmeter, Derek , Nicollet, Park, Abullarade, Carol, Keune, Shelly, Smith, Timothy D. , Barksdale, Bryan, Peters, Roma, Price, Memrie, Watson, Connie, Wolfe, Douglas A. , Haynes, Brian, Daniels, Paul R. , Jaeger, Thomas M. , McCarthy, Sarah R. , Hargraves, Ian G, Sivly, Angela L, Suzuki, Takeki , Jackson, Elizabeth A , McCarthy, Sarah R , Montori, Victor M , Noseworthy, Peter A , Branda, Megan , Brito, Juan P , Burnett, Bruce, Linzer, Mark , Jackson, Elizabeth A. , Hess, Erik P. , Montori, Víctor M. , Fleming, Kirsten, Burnett, Bruce, Hamilton, James, Simpson, Benjamin, Bellolio, Fernanda , Fleming, Kirsten, LeBlanc, Annie , Lee, Alexander , Burnett, Bruce, Harvey, Lisa Anne , Stephens, Shannon W. , Hamilton, James, Hickey, Theresa, Guyatt, Gordon , Tomlinson, George , Gersh, Bernard J. , McBane, Robert D. , McCarthy, Sarah R.

Mayo Clinic

Journal of the American Heart Association | January 13, 2022 | Volume: 11 | Issue: 2 | Pages: No page available

10.1161/jaha.121.023048 | PMID 35023356 Get It

Background Guidelines promote shared decision‐making (SDM) for anticoagulation in patients with atrial fibrillation. We recently showed that adding a within‐encounter SDM tool to usual care (UC) increases patient involvement in decision‐making and clinician satisfaction, without affecting encounter length. We aimed to estimate the extent to which use of an SDM tool changed adherence to the decided care plan and clinical safety end points. Methods and Results We conducted a multicenter, encounter‐level, randomized trial assessing the efficacy of UC with versus without an SDM conversation tool for use during the clinical encounter (Anticoagulation Choice) in patients with nonvalvular atrial fibrillation considering starting or reviewing anticoagulation treatment. We conducted a chart and pharmacy review, blinded to randomization status, at 10 months after enrollment to assess primary adherence (proportion of patients who were prescribed an anticoagulant who filled their first prescription) and secondary adherence (estimated using the proportion of days for which treatment was supplied and filled for direct oral anticoagulant, and as time in therapeutic range for warfarin). We also noted any strokes, transient ischemic attacks, major bleeding, or deaths as safety end points. We enrolled 922 evaluable patient encounters (Anticoagulation Choice=463, and UC=459), of which 814 (88%) had pharmacy and clinical follow‐up. We found no differences between arms in either primary adherence (78% of patients in the SDM arm filled their first prescription versus 81% in UC arm) or secondary adherence to anticoagulation (percentage days covered of the direct oral anticoagulant was 74.1% in SDM versus 71.6% in UC; time in therapeutic range for warfarin was 66.6% in SDM versus 64.4% in UC). Safety outcomes, mostly bleeds, occurred in 13% of participants in the SDM arm and 14% in the UC arm. Conclusions In this large, randomized trial comparing UC with a tool to promote SDM against UC alone, we found no significant differences between arms in primary or secondary adherence to anticoagulation or in clinical safety outcomes. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: clinicaltrials.gov. Identifier: NCT02905032.
Cost Conversations About Anticoagulation Between Patients With Atrial Fibrillation and Their Clinicians
Giblon, Rachel , Kunneman, Marlene, Lee, Alexander I., Hargraves, Ian , Sivly, Angela , Burnett, Bruce , Gorr, Haeshik, Roldan, Victor D. Torres , Spencer-Bonilla, Gabriella, Shah, Nilay D. , Brito, Juan P. , Investigators, Shared Decision Making for Atrial Fibrillation (SDM4AFib) Trial, Haffke, Alexander, Stier, Amy, Thota, Anjali, Simpson, Benjamin , Zeballos‐Palacios, Claudia , Vanmeter, Derek , Behnken, Emma , Ting, Henry H. , Anderson, Joel, Inselman, Jonathan , Muegge, Jule , Fleming, Kirsten, Olive, Marc, Vang, Miamoua, Ferrara, Michael J. , Wambua, Mike , Organick, Paige, Cabalka, Renee, Poplau, Sara , Abullarade, Carol, Keune, Shelly, Smith, Timothy D. , Barksdale, Bryan, Peters, Roma, Price, Memrie, Watson, Connie, Wolfe, Douglas A. , Haynes, Brian, Daniels, Paul R. , Jaeger, Thomas M. , Kamath, Celia C , Branda, Megan E. , Hargraves, Ian G, Sivly, Angela L, Torres Roldan, Victor D , Brito, Juan P , Kamath, Celia , Lee, Alexander I., Bellolio, Fernanda , Jackson, Elizabeth A. , Burnett, Bruce, Noseworthy, Peter A. , Montori, Víctor M. , Investigators, Shared Decision Making for Atrial Fibrillation (SDM4AFib) Trial, LeBlanc, Annie , Hess, Erik P. , Hamilton, James, Fleming, Kirsten, Linzer, Mark , Suzuki, Takeki , Harvey, Lisa Anne , Stephens, Shannon W. , Hickey, Theresa, Guyatt, Gordon , Tomlinson, George , Gersh, Bernard J. , McBane, Robert D.

Mayo Clinic

JAMA Network Open | July 13, 2021 | Volume: 4 | Issue: 7 | Pages: e2116009

10.1001/jamanetworkopen.2021.16009 | PMID 34255051 Get It

Abstract 13781: Recurrence of Papillary Fibroelastoma
Sorour, Ahmed A. , Kurmann, Reto , El‐Am, Edward , Bois, Melanie C. , Maleszewski, Joseph J. , Klarich, Kyle W. , Scott, Christopher G. , Lee, Alexander , Dearani, Joseph A.

Mayo Clinic

Circulation | May 10, 2021 | Volume: 142 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.142.suppl_3.13781 Get It

Background: Papillary fibroelastoma (PFE) is the most common benign cardiac tumor. Because PFEs have the potential to embolize, they typically are surgically excised. Prior studies have suggested that postoperative recurrence of PFE is rare or does not occur. Objectives: To determine the rate at which PFEs recurred after surgical removal and to identify any risk factors associated with recurrence. Methods: Patients with pathologically proven PFE were retrospectively identified from a single center. Patients were included in the study if they had an echocardiographic examination at least 1 year after surgery. Echocardiographic images obtained intraoperatively (after excision) and at dismissal were compared with those of the most recent examination to assess the possibility of PFE recurrence. Results: Ninety eight patients were identified. The mean (SD) duration of follow-up was 5.4 (3.7) years (range, 1-17 years). Twelve patients (12.2%) had echocardiographically proven PFE recurrence. Three patients had the recurrent lesion surgically re-excised, and pathologic analysis showed that 2 were recurrent PFEs and 1 was a Lambl excrescence. Clinical presentation of stroke or TIA was more common for the recurrence patients (for the first PFE) than for the nonrecurrence patients (83% vs 26%; P <.001). Conclusions: Contrary to published data, PFEs do recur after surgical excision. This emphasizes the importance of postoperative follow-up with transesophageal echocardiography for identifying recurrent masses. Table. Characteristics of Patients With Recurrent PFE Abbreviations: AV, aortic valve; LA, left atrium; LE, Lambl excrescence; LVOT, left ventricular outflow tract; MV, mitral valve; PV, pulmonary valve; RA, right atrium; RC, right cusp; TV, tricuspid valve. a Corresponds to the same location. b Corresponds to a different location .
Effectiveness of a Weight Loss Program Using Digital Health in Adolescents and Preadolescents
Lei, Sha , Medina‐Inojosa, José R. , Kumar, Seema, Lee, Alexander T., Lerman, Lilach O. , Senecal, Conor , Lin, Weihua, Inojosa, Jose R Medina, Senecal, Conor G, Medina-Inojosa, José R , Scott, Christopher G. , Lerman, Amir , Zhang, Xiaoyong , Cohen, Pinchas , López-Jiménez, Francisco

Mayo Clinic

Childhood Obesity | April 7, 2021 | Volume: 17 | Issue: 5 | Pages: 311-321

10.1089/chi.2020.0317 | PMID 33826417 Get It

Objective: To identify an efficacious intervention on treating adolescents with overweight and obesity, this might result in health benefits. Methods: Adolescents with overweight or obesity aged 10–17 years with BMI percentile ≥85th were included in this historical observational analysis. Subjects used an entirely remote weight loss program combining mobile applications, frequent self-weighing, and calorie restriction with meal replacement. Body weight changes were evaluated at 42, 60, 90, and 120 days using different metrics including absolute body weight, BMI, and BMI z-score. Chi-square or Fisher exact tests (categorical variables) and Student's t -test (continuous variables) were used to compare subjects. Results: In total, 2,825 participants, mean age 14.4 ± 2.2 years, (54.8% girls), were included from October 27, 2016, to December 31, 2017, in mainland China; 1355 (48.0%) had a baseline BMI percentile ≥97th. Mean BMI and BMI z-score were 29.20 ± 4.44 kg/m 2 and 1.89 ± 0.42, respectively. At day 120, mean reduction in body weight, BMI, and BMI z-score was 8.6 ± 0.63 kg, 3.13 ± 0.21 kg/m 2 , and 0.42 ± 0.03; 71.4% had lost ≥5% body weight, 69.4% of boys and 73.2% of girls, respectively. Compared with boys, girls achieved greater reduction on BMI z-score at all intervals ( p < 0.004 for all comparisons). Higher BMI percentile at baseline and increased frequency of use of the mobile application were directly associated with more significant weight loss. Conclusions: An entirely remote digital weight loss program is effective in facilitating weight loss in adolescents with overweight or obesity in the short term and mid term.
Don’t Be Blue: A Case Series Describing Colonoscope Damage After Chromoendoscopy for Surveillance of Dysplasia in Inflammatory Bowel Disease
Lee, Alexander S. , Hubers, Jeffrey , Osman, Fauzia , Caldera, Freddy , Saha, Sumona , Caldera, Freddy

Mayo Clinic

Inflammatory Bowel Diseases | April 6, 2020 | Volume: 26 | Issue: 6 | Pages: e54-e54

10.1093/ibd/izaa068 | PMID 32249905 Get It